+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Effects of age and polytherapy, risk factors of valproic acid hepatotoxicity, on the excretion of thiol conjugates of -2,4-diene VPA in people with epilepsy taking VPA

Effects of age and polytherapy, risk factors of valproic acid hepatotoxicity, on the excretion of thiol conjugates of -2,4-diene VPA in people with epilepsy taking VPA

Epilepsia 44(3): 322-328

Purpose: Valproic acid (VPA) is an antiepileptic drug (AED) used for generalized and absence seizures. It has a rare but potentially fatal hepatotoxicity side effect, and many researchers believe that reactive metabolites of VPA could be involved. We demonstrated here that the thiol conjugates of (E)-2,4-diene VPA were significantly elevated in a high-risk group of patients. Methods: Thirty-four patients with seizures were divided into three groups. Group A (n = 14) were being treated with VPA; group B (n = 12) received VPA as well as other AEDs that do not induce P450-VPA metabolism; and group C (n = 8) received VPA and AEDs that induce P450-VPA metabolism. The NAC conjugates of (E)-2,4-diene VPA (NAC I and NAC II) were identified in the urine of patients by gas chromatography/mass spectrography NICI analysis. Results: VPA monotherapy (group A) or VPA polytherapy with non-P450-enzyme-inducing drugs (group B), showed that patients younger than 7.5 years excreted significantly higher concentrations of the two conjugates compared with older patients (older than 7.5 years) in the same groups (p < 0.05). Patients receiving VPA polytherapy with P450-enzyme-inducing drugs were all older than 7.5 years (group C). They excreted significantly higher concentrations of NAC I and NAC II compared with patients in groups A and B who were older than 7.5 years (p < 0.05). Conclusions: There were no significant differences in the excretion of NAC I and NAC II between patients in group C and those who were 7.5 years or younger in groups A and B. High doses of VPA also were a significant factor associated with elevated NAC I and NAC II among young patients and in polytherapy patients.

(PDF emailed within 1 workday: $29.90)

Accession: 034814037

Download citation: RISBibTeXText

Related references

Mechanistic studies of valproic acid hepatotoxicity identification and characterization of thiol conjugates. Pharmaceutical Research (New York) 8(10 SUPPL): S1, 1991

Transitional polytherapy, liver enzymes, and valproic acid hepatotoxicity. Neurology 37(10): 1692-1693, 1987

Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes. Toxicology and Applied Pharmacology 264(3): 413-422, 2012

Experimental study on susceptibility of high risk factors related with hepatotoxicity of valproic acid. Zhongguo Yaolixue Tongbao 21(11): 1375-1381, 2005

Evaluation of Binding Equation Method for Unbound Serum Concentration Prediction of Valproic Acid in Polytherapy Pediatric Patients with Epilepsy. American Journal of Therapeutics 2(2): 106-111, 1995

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine 93(11): E66, 2014

Thromboembolic risk factors in children with epilepsy treated with valproic acid. Epilepsia 45(Suppl 3): 132, 2004

Risk factors for valproic acid resistance in childhood absence epilepsy. Seizure 18(10): 690-694, 2010

Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Research 101(3): 202-209, 2013

Pharmacology of valproic acid in children with severe epilepsy: clearance and hepatotoxicity. Neurology 31(8): 1047-1050, 1981

Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. Basic and Clinical Pharmacology and Toxicology 123(5): 628-634, 2018

Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clinical Pharmacology and Therapeutics 48(3): 225-235, 1990

Carnitine supplementation in adult patients with hypocarnitinemia taking valproic acid for epilepsy. Epilepsia 42(Supplement 7): 256, 2001

Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha: implication for valproic acid-associated hepatotoxicity syndrome. Biochemical Pharmacology 58(3): 455-459, 1999

Pharmacokinetics of valproic acid in monotherapy and polytherapy. Farmacia Clinica 4(4): 310-312, 314-316, 318, 1987